MedTrace Logo

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02684370 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2021-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Conditions

Interventions

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo for risankizumab administered by subcutaneous (SC) injection

DRUG

ustekinumab

Ustekinumab administered by subcutaneous (SC) injection

DRUG

placebo for ustekinumab

Placebo for ustekinumab administered by subcutaneous (SC) injection

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-12-31
Completion
2017-09-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684370 on ClinicalTrials.gov